Glenmark Pharmaceuticals Limited
GLENMARK.NS
1417.4
INR+35.70
(+2.58%)Day's range
1383.7
1428.5
52 wk Range
985.2
1830.95
Key ratios
Statements Highlights
| Period Ending | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | |
|---|---|---|---|---|---|---|
| Total Revenue | 106,572,620,000 | 108,060,260,000 | 121,741,980,000 | 115,832,350,000 | 118,130,970,000 | |
| Gross Profit | 35,417,560,000 | 35,802,940,000 | 41,087,340,000 | 36,301,950,000 | 32,592,800,000 | |
| Operating Income | 12,820,890,000 | 17,160,360,000 | 18,400,480,000 | 10,788,740,000 | 6,310,730,000 | |
| Net Income | 7,759,700,000 | 9,700,380,000 | 9,417,110,000 | 2,972,450,000 | -15,016,680,000 | |
| Total Assets | 146,848,070,000 | 156,035,770,000 | 170,832,880,000 | 193,716,760,000 | 143,586,240,000 | |
| Total Current Liabilities | 41,259,830,000 | 42,010,200,000 | 46,894,310,000 | 51,050,560,000 | 58,185,870,000 | |
| Total Equity | 60,701,130,000 | 70,642,730,000 | 94,381,200,000 | 98,392,590,000 | 78,475,470,000 | |
| Free Cash Flow | 4,610,400,000 | 3,564,550,000 | 3,185,350,000 | 176,290,000 | -11,638,220,000 | |
| Cash from Operations | 13,924,130,000 | 11,312,130,000 | 11,086,520,000 | 6,253,920,000 | -2,654,440,000 | |
| Cash from Investing | -7,835,170,000 | -6,752,360,000 | -3,332,800,000 | -5,284,910,000 | 45,437,300,000 | |
| Cash from Financing | -4,446,630,000 | -4,417,790,000 | -5,204,910,000 | -774,560,000 | -39,061,270,000 | |
| Net Change in Cash | 1,739,970,000 | 278,200,000 | 2,724,310,000 | 325,000,000 | 2,152,440,000 |